Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Microenvironment
Published in: Cancer Microenvironment 1-3/2017

01-12-2017 | Short Communication

The Impact of Microenvironment on the Synovial Sarcoma Transcriptome

Authors: Huifeng Jin, Jared J. Barrott, Matthew G. Cable, Michael J. Monument, Daniel M. Lerman, Kyllie Smith-Fry, Dakota Nollner, Kevin B. Jones

Published in: Cancer Microenvironment | Issue 1-3/2017

Login to get access

Abstract

Synovial sarcoma (SS) is initiated by a t(X;18) chromosomal translocation and resultant SS18-SSX fusion oncogene. Only a few SS cell lines exist. None has been compared to its source tumor. In order to compare matched tumor and cell line pairs, we performed RNAseq on 3 tumor/cell line pairs from a genetically engineered mouse model of SS, as well as 2 pairs from human SS tumors. Transcriptomes of mouse tumors and derivative cell lines deviated significantly. Differentially expressed genes highlighted inflammatory infiltrates and metabolism. The same was found for the human tumor and cell line pairs. More was shared between different tumors than between any tumor and its cell line. Direct xenografting generated transcriptomes that more closely resembled the primary tumor than did its derivative cell line. SS tumor transcriptomes are powerfully impacted by the environment wherein they reside, especially with regard to immune interaction and metabolism.
Literature
1.
Begley CG, Ellis LM (2012) Drug development: raise standards for preclinical cancer research. Nature 483(7391):531–533CrossRefPubMed
2.
Herzog CE (2005) Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol 27(4):215–218CrossRefPubMed
3.
Vlenterie M, Litiere S, Rizzo E, Marreaud S, Judson I, Gelderblom H, Le Cesne A, Wardelmann E, Messiou C, Gronchi A, van der Graaf WT (2016) Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer soft tissue and bone sarcoma group; setting a new landmark for studies in this entity. Eur J Cancer 58:62–72CrossRefPubMed
4.
Jones KB, Barrott JJ, Xie M, Haldar M, Jin H, Zhu JF, Monument MJ, Mosbruger TL, Langer EM, Randall RL, Wilson RK, Cairns BR, Ding L, Capecchi MR (2016) The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis. Oncogene 35:5021–5032CrossRefPubMedPubMedCentral
5.
Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, Gusterson BA, Cooper CS (1994) Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 7(4):502–508CrossRefPubMed
6.
de Leeuw B, Balemans M, Olde Weghuis D (1995) Geurts van Kessel a. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum Mol Genet 4(6):1097–1099CrossRefPubMed
7.
Kottu R, Prayaga AK (2010) Synovial sarcoma with relevant immunocytochemistry and special emphasis on the monophasic fibrous variant. J Cytol 27(2):47–50CrossRefPubMedPubMedCentral
8.
Sherr CJ, DePinho RA (2000) Cellular senescence: mitotic clock or culture shock? Cell 102(4):407–410CrossRefPubMed
9.
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57(1):289–300
10.
11.
Sandberg R, Ernberg I (2005) Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc Natl Acad Sci U S A 102(6):2052–2057CrossRefPubMedPubMedCentral
12.
Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N, Kusuzaki K, Nakayama T, Tsuboyama T, Nakamura T, Imamura M, Nakamura Y, Toguchida J (2002) Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 62(20):5859–5866PubMed
13.
Allander SV, Illei PB, Chen Y, Antonescu CR, Bittner M, Ladanyi M, Meltzer PS (2002) Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161(5):1587–1595CrossRefPubMedPubMedCentral
14.
Fernebro J, Francis P, Eden P, Borg A, Panagopoulos I, Mertens F, Vallon-Christersson J, Akerman M, Rydholm A, Bauer HC, Mandahl N, Nilbert M (2006) Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 118(5):1165–1172CrossRefPubMed
15.
Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24(3):227–235CrossRefPubMed
Metadata
Title
The Impact of Microenvironment on the Synovial Sarcoma Transcriptome
Authors
Huifeng Jin
Jared J. Barrott
Matthew G. Cable
Michael J. Monument
Daniel M. Lerman
Kyllie Smith-Fry
Dakota Nollner
Kevin B. Jones
Publication date
01-12-2017
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 1-3/2017
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-017-0192-y

Other articles of this Issue 1-3/2017

Cancer Microenvironment 1-3/2017 Go to the issue

Original Article

Effects of Vacuolar H+-ATPase Inhibition on Activation of Cathepsin B and Cathepsin L Secreted from MDA-MB231 Breast Cancer Cells

Original Article

Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche

Original Article

Participation of Tumor-Associated Myeloid Cells in Progression of Amelanotic Melanoma (RMM Tumor Line) in F344 Rats, with Particular Reference to MHC Class II- and CD163-Expressing Cells

Original Article

Epithelial Mesenchymal Transition (EMT) in Metastatic Breast Cancer in Omani Women

Original Article

Upregulation of Treg-Related Genes in Addition with IL6 Showed the Significant Role for the Distant Metastasis in Colorectal Cancer

Original Article

Prognostic Prediction of Oral Squamous Cell Carcinoma by E-Cadherin and N-Cadherin Expression in Overall Cells in Tumor Nests or Tumor Cells at the Invasive Front
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits